The Rise of Humira Biosimilars and the Adoption Challenge

AbbVie’s Humira—the most financially successful drug in history—said goodbye to two decades of U.S. market exclusivity back in January when Amgen’s Humira biosimilar, Amjevita, hit the U.S. market. Now, seven months later, several new Humira biosimilars are hitting the U.S. market. In this article, I’ll highlight how several drugmakers broke through Humira’s patent fortress, discuss the latest…

Read More

Context Means Clarity

I have lost count of the number of times I have shared feedback intending for it to come across a certain way, only for the other person to receive it completely differently. I am sure you have been there too and it can be incredibly frustrating, especially when your intentions are pure. But, looking back…

Read More

Navigating the Digital Health Funding Landscape: Insights from H1 2023

Rock Health’s latest digital health funding report hinted that funding in 2023 is on path to be the lowest funding year since 2019. Am I shocked? Nope. This latest funding trend has been something folks in the digital health community have been expecting since the 2021 funding boom. Some have even been expecting it since 2019! In…

Read More

Set & Raise The Bar

Think of the last time you felt inspired. What underpinned the feeling? Was it a person and the words they said or simply being in a new environment? Whatever it was, you want to capture that feeling and commit to ensuring your sellers feel the same way every time you talk. Elite performance starts with…

Read More

Cost Plus Drugs: Key Updates from H1 ‘23

Mark Cuban’s Cost Plus Drug company is moving so fast that I’m struggling to keep up. I last covered Cost Plus Drugs in January when I recapped the progress the company made in 2022. I was planning on waiting a year to do another recap, but for the sake of you and me, I need to do a mid-year…

Read More

Act Early, Don’t Wait

One of the biggest shortcomings of SaaS Sales Leaders is hesitating to address underperformance. When a seller isn’t driving revenue, they compromise themselves, you as their leader and the company. Whenever I have seen challenges with morale, 90% of the time it’s due to poor performance. High-performing salespeople are happier; poor performers will typically pull…

Read More